13F Portfolios

Tetragon Partners GP Ltd — NEKTAR THERAPEUTICS NKTR: Quarterly 13F Position History

Tetragon Partners GP Ltd has reported NEKTAR THERAPEUTICS (NKTR) on 2 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2025. As of Q1 2026, the position is sized at 103,037 shares ($7.4M market value, 1.46% of the equity book). Quarter-over-quarter share count change: + 33,750 (+48.7%) .

Recent initiation: Tetragon Partners GP Ltd first reported NKTR on the Q4 2025 filing — fewer than three quarters of history are available.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 103,037 +33,750 +48.7% $7.4M 1.46% $71.95
Q4 2025 69,287 $2.9M 0.62% $42.28

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Tetragon Partners GP Ltd first disclose a NKTR position in 13F-HR filings?

Tetragon Partners GP Ltd first reported NEKTAR THERAPEUTICS (NKTR) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.

What was Tetragon Partners GP Ltd's most recent quarter-over-quarter share-count change in NKTR?

Between Q4 2025 and Q1 2026, Tetragon Partners GP Ltd added 33,750 shares of NKTR (+48.7%), bringing the total reported position to 103,037 shares at a market value of $7.4M.

Does the implied price-per-share represent Tetragon Partners GP Ltd's cost basis in NKTR?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.